Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) SHZ
Currency In CNY
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In CNY
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
553
First IPO Date
January 12, 2017
| Name | Title | Pay | Year Born |
| Guangyao Liu | Deputy General Manager | 0 | 1989 |
| Wei Biao Yue | Deputy General Manager | 0 | 1970 |
| Xiaowei Li | Accounting Supervisor | 0 | N/A |
| Yuping Cao | GM & Chairman of the Board | 0 | 1964 |
| Mingsheng Feng | Deputy GM & Director | 0 | 1978 |
| Li Qun Wang | Secretary & Deputy GM | 0 | 1988 |
| Jian Ren Chen | Financial Director | 0 | 1969 |
Nanjing Hicin Pharmaceutical Co., Ltd. (NHPC), established in 2003 and headquartered in Nanjing, China, operates as a comprehensive enterprise specializing in the research, development, production, marketing, and distribution of pharmaceutical preparations and synthetic chemicals within China. The company boasts a diverse product portfolio, addressing various therapeutic areas such as antivirals, antibiotics, endocrine regulators, gastrointestinal treatments, orthopedic medications, cardiovascular and cerebrovascular drugs, and immunomodulatory agents. Beyond its core pharmaceutical activities, NHPC also provides technology transfer services. On an international scale, Nanjing Hicin Pharmaceutical Co., Ltd. is a supplier of Active Pharmaceutical Ingredients (APIs). Its export offerings specifically include injectable forms of omeprazole sodium and cefepime hydrochloride, along with lansoprazole tablets, which reach markets across South Asia, South America, and Europe.